Healwell AI Launches Patient-Consent Platform in Strategic Push

Healwell AI and WELL Health launch WELLTRUST™, a consent-first platform using AI to recruit patients for clinical trials from a network of 240+ clinics.

Healwell AI Inc. is tackling a critical bottleneck in clinical research—patient recruitment—by leveraging a sensitive commodity: health data. In partnership with WELL Health Technologies, the company has initiated a new platform that contacts patients for medical trials strictly after obtaining their active consent. This operational move aims to transform the company's strategic announcements into tangible commercial activity.

Strategic Imperative and Commercial Scale

The launch represents a significant commercial milestone within Healwell AI's partnership with its key strategic ally, WELL Health. The potential scale is substantial, drawing on WELL Health's network of more than 240 clinics and over 43,000 healthcare providers across the United States and Canada. By integrating Healwell's validated artificial intelligence, the partners intend to create a scalable recruitment solution for clinical studies.

WELLTRUST™: A "Consent-First" Framework

The core of the new WELLTRUST™ platform is its foundational "consent-first" principle. Patients receiving care at WELL-operated clinics in Canada can voluntarily opt-in to be contacted regarding potential clinical trial participation. Those who decline will continue to receive standard care without any alteration to their treatment, according to the joint announcement.

For its initial commercial application, the platform utilizes Healwell's DARWEN™ AI engine. This technology screens the pool of consenting patients to precisely identify individuals with chronic, rare, or complex diseases who may qualify for specific research protocols. The industry-wide challenge of finding suitable participants is often a protracted and costly process.

Integration and Broader Roadmap

The WELLTRUST platform follows a series of internal integration steps previously outlined by Healwell in a corporate update dated February 12. The company consolidated AI capabilities from its Khure and Pentavere acquisitions into a unified DARWEN-based engine. It also merged its operational and sales teams and expanded cross-selling through coordinated Orion-Verosource initiatives.

Concurrently, the same update detailed Healwell's broader timeline. The North American launch of Amadeus AI, a digital, AI-powered patient health record system, is scheduled for the first half of 2026, with international expansion to follow by late 2026. Furthermore, Healwell is evaluating a strategic investment vehicle exceeding $2 million USD that holds a stake in xAI. The update noted that xAI merged with SpaceX on February 2, 2026.

Share Performance Contrasts Operational Progress

Despite these operational developments, Healwell AI's shares continue to face selling pressure. The stock closed at €0.39 on Friday, hovering near its 52-week low. This price level underscores the pessimistic market sentiment that has persisted over recent months.

Investors may soon gain clearer insight. The company's full-year financial results are anticipated by late March 2026. These figures are expected to reveal whether the new platform and deepened integration with WELL Health are beginning to generate measurable revenue or demonstrate concrete commercial progress.